Anticancer agent 306 

Anticancer agent 306 is a spiro tetramic acid derivative and a inhibitor of MMP1, MMP7 and PLK1. Anticancer agent 306 exerts antiproliferative activity against H1299, RKO and MCF-7 cells with IC₅₀ values of 19.25 μM, 3.29 μM and 102.36 μM, respectively. Anticancer agent 306 can up-regulate p21 protein and down-regulate CCND1 and CCNB1 proteins to induce cell cycle arrest, regulate the expression of Bcl-2 and Bax to induce cell apoptosis. Anticancer agent 306 can down-regulate MMP1 and MMP7 proteins to inhibit tumor invasion and metastasis. Anticancer agent 306 can be used for the research of lung cancer, colorectal cancer, breast cancer^[1].

Anticancer agent 306 (8D) potently inhibits the proliferation of H1299, RKO, and MCF-7 cells with IC₅₀ values of 19.25 μM, 3.29 μM, and 102.36 μM, respectively^[1].
Anticancer agent 306 (10-40 μg/mL) dose-dependently down-regulates MMP1, MMP7, PLK1, CCND1, and Bcl-2, and up-regulates p21, Bax, caspase-3, and caspase-8 in H1299 and RKO cells^[1].
Anticancer agent 306 (10-40 μg/mL) induces G1-phase cell cycle arrest in H1299 and RKO cells, with a corresponding decrease in S and G2 phase cell proportions^[1].
Anticancer agent 306 (10-40 μg/mL) dose-dependently induces early and late apoptosis in H1299 and RKO cells, via the mitochondrial pathway^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

382.28

C₁₉H₂₁Cl₂NO₃

3043892-01-6

ClC1=CC(Cl)=C(C2=C(OC(CC(C)C)=O)C3(CCCC3)NC2=O)C=C1

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Xiang S, et al. Design, synthesis, and mechanism of anti-cancer activity of novel spiro tetramic acids. Bioorg Med Chem Lett. 2026;135:130566.  [Content Brief]